Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgrastim in Severe Bullous Drug Eruptions (SJS/TEN)
NCT04651439Phase 3Recruiting
- Sponsor
- Hospices Civils de Lyon
- Start
- May 2022
- Primary completion
- May 2025
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 3 trial of filgrastim in toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), sponsored by Hospices Civils de Lyon. Started May 2022; status: recruiting.
02
Drugs
filgrastim
03
Conditions
toxic epidermal necrolysis (TEN)Stevens-Johnson syndrome (SJS)
Beyond the preview
Go deeper on NCT04651439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04651439.